GlassScriptPhysician profile
Brian J Anseeuw
NPI 1568476117
$29,393.22
in general payments reported to CMS, 2019-2025
58 companies · $2,432 in 2025
The $2,432 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $5,414 · 2021: $7,780 · 2022: $7,998 · 2023: $1,874 · 2024: $2,551 · 2025: $2,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,469 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $338 · Education: $51.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,468.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $337.50 |
| Education | $51.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,007.53 | 2019-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $5,031.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $1,009.01 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $846.84 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Novartis Pharmaceuticals Corporation | $689.08 | 2019-2025 | |
| Eisai INC. | $674.51 | 2019-2025 | |
| Lundbeck LLC | $642.92 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $579.17 | 2019-2025 | |
| Biogen, INC. | $559.10 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
| Avanir Pharmaceuticals, INC. | $471.17 | 2019-2022 | |
| Csl Behring | $468.90 | 2019-2025 | Hizentra |
| Mallinckrodt Hospital Products INC. | $238.59 | 2021-2025 | Acthar |
| Livanova USA, INC. | $235.45 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $228.88 | 2019-2025 | Rystiggo |
| Supernus Pharmaceuticals, INC. | $226.90 | 2019-2025 | Qelbree |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $215.07 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Amgen INC. | $207.88 | 2019-2022 | |
| Sk Life Science, INC. | $189.02 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $181.82 | 2020-2022 | |
| Harmony Biosciences LLC | $180.21 | 2022-2025 | Wakix |
| Acadia Pharmaceuticals INC | $179.55 | 2019-2025 | Nuplazid, Daybue |
| Acorda Therapeutics, INC | $164.50 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $160.14 | 2022 | |
| Neurocrine Biosciences, INC. | $142.00 | 2021-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $132.98 | 2024-2025 | Hyqvia |
| Celgene Corporation | $130.07 | 2021-2024 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $122.14 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $118.00 | 2025 | Xeomin, Inbrija, Ampyra |
| Argenx US, INC. | $116.25 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $115.13 | 2020-2024 | Fycompa |
| Amneal Pharmaceuticals LLC | $93.58 | 2019-2023 | Rytary |
| Alexion Pharmaceuticals, INC. | $88.59 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $86.53 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $78.53 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $72.18 | 2023 | Aptiom |
| Kyowa Kirin, INC. | $69.67 | 2019-2023 | Nourianz |
| Medtronic USA, INC. | $68.60 | 2019-2020 | |
| Medtronic, INC. | $64.65 | 2021-2022 | |
| Axsome Therapeutics, INC. | $57.96 | 2023-2025 | Sunosi, Symbravo |
| Tanabe Pharma America, INC. | $57.77 | 2025 | Radicava |
| Emd Serono, INC. | $47.60 | 2019-2023 | Mavenclad |
| Genentech USA, INC. | $33.20 | 2022-2023 | Enspryng, Ocrevus |
| Janssen Biotech, INC. | $27.65 | 2025 | |
| Portola Pharmaceuticals, LLC | $27.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.04 | 2023 | |
| Janssen Pharmaceuticals, INC | $23.86 | 2022 | |
| Boston Scientific Corporation | $21.64 | 2020 | |
| Impel Pharmaceuticals INC. | $21.57 | 2023 | Trudhesa |
| Genzyme Corporation | $20.45 | 2019 | |
| Alfasigma USA, INC. | $19.29 | 2020 | |
| Avion Pharmaceuticals | $18.28 | 2022 | |
| Abbott Laboratories | $17.82 | 2021 | |
| Itamar Medical INC | $17.80 | 2024 | Watchpatone |
| Idorsia Pharmaceuticals US INC | $15.44 | 2024 | Quviviq |
| Grifols USA, LLC | $14.67 | 2025 | Prolastin-C Liquid |
| Mallinckrodt Enterprises LLC | $13.76 | 2019 | |
| Kedrion Biopharma, INC. | $13.41 | 2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Merz North America, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Anseeuw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.